Zkusit zdarma
Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

ALLO
Cena:
$ 2.00
+0.04 (2.04%)
Valuace
70
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

11:21 14-05-2026

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from...

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

7:50 14-05-2026

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript...

Allogene Therapeutics Q1 Earnings Call Highlights

Allogene Therapeutics Q1 Earnings Call Highlights

20:15 13-05-2026

Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progr...

Allogene Therapeutics ends China cell therapy deal with Overland

Allogene Therapeutics ends China cell therapy deal with Overland

17:05 13-05-2026

Allogene Therapeutics said on Wednesday it has ended a key partnership for ​developing cell therap...

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

16:02 13-05-2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A...

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

8:30 06-05-2026

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, C...

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

8:30 21-04-2026

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 13.1% After Analyst Upgrade

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 13.1% After Analyst Upgrade

1:48 17-04-2026

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day tra...

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

16:01 16-04-2026

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

8:30 15-04-2026

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

21:50 14-04-2026

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

13:15 14-04-2026

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling pote...

Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)

Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)

1:08 14-04-2026

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options ...

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

16:01 13-04-2026

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

13:41 13-04-2026

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3...

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

7:30 13-04-2026

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningfu...

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

16:02 10-04-2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Rises By 19.8%

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Rises By 19.8%

2:29 17-03-2026

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) saw a significant increase in short int...

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

12:25 13-03-2026

ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash...

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

2:22 13-03-2026

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript...

close

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

05-02-2026
SOUTH SAN FRANCISCO, CALIF., FEB. 05, 2026 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS POSITIONS 2026 AS A PROGRAM-DEFINING YEAR FOR SCALABLE, REAL-WORLD ALLOGENEIC CAR T

08-01-2026
SOUTH SAN FRANCISCO, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS REPORTS FAVORABLE RESULT FOR SERVIER IN ARBITRATION WITH CELLECTIS

15-12-2025
ARBITRATION RULING REAFFIRMS ALLOGENE'S FULL CONTROL OF CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) DECIS...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

10-11-2025
SOUTH SAN FRANCISCO, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

06-11-2025
PIVOTAL PHASE 2 ALPHA3 TRIAL WITH CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST LINE (1L) CONSOLID...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES ALPHA3 TRIAL-IN-PROGRESS POSTER PRESENTATION AT ASH ANNUAL MEETING

03-11-2025
SOUTH SAN FRANCISCO, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

30-10-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR NOVEMBER 6, 2025 AT 2:00 P.M. PT/5:00 P.M....
Více zde

ALLO ENABLES EQUAL ACCESS TO SECURE WI-FI FOR ALL STUDENTS WITH CALIX SMARTTOWN FOR EDUCATION

17-10-2025
LINCOLN, NEB. & SAN JOSE, CALIF.--(BUSINESS WIRE)---- $CALX #CALIX--CALIX, INC. (NYSE: CALX) TODAY A...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCE

27-08-2025
SOUTH SAN FRANCISCO, CALIF., AUG. 27, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

13-08-2025
SOUTH SAN FRANCISCO, CALIF., AUG. 13, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

ALLOGENE THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

06-08-2025
SOUTH SAN FRANCISCO, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

ALLOGENE THERAPEUTICS MOVES FORWARD WITH STANDARD FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) LYMPHODEPLETION REGIMEN IN THE ALPHA3 TRIAL FOR CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE CONSOLIDATION FOR LARGE B-CELL LYMPHOMA

01-08-2025
SOUTH SAN FRANCISCO, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

ALLOGENE THERAPEUTICS PROVIDES UPDATED PHASE 1 DATA HIGHLIGHTING DURABLE RESPONSES WITH ALLO-316 IN HEAVILY PRETREATED ADVANCED RENAL CELL CARCINOMA AT ASCO

01-06-2025
SOUTH SAN FRANCISCO, CALIF., JUNE 01, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

23-05-2025
SOUTH SAN FRANCISCO, CALIF., MAY 23, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: A...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES ASCO 2025 ABSTRACT PUBLICATION FEATURING ORAL PRESENTATION OF ALLO-316 IN KIDNEY CANCER AND ALPHA3 TIP POSTER FOR CEMA-CEL

22-05-2025
SOUTH SAN FRANCISCO, CALIF., MAY 22, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: A...
Více zde

ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

13-05-2025
PIVOTAL PHASE 2 ALPHA3 TRIAL WITH CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST LINE (1L) CONSOLID...
Více zde

ALLOGENE THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

06-05-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR MAY 13, 2025 AT 2:00 P.M. PT/5:00 P.M....
Více zde

ALLOGENE THERAPEUTICS TO PRESENT UPDATED ALLO-316 CLINICAL RESULTS IN KIDNEY CANCER IN ORAL PRESENTATION AND ALPHA3 TRIAL-IN-PROGRESS POSTER FOR CEMA-CEL AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

23-04-2025
SOUTH SAN FRANCISCO, CALIF., APRIL 23, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

ALLOGENE GRANTED THREE U.S. FDA FAST TRACK DESIGNATIONS (FTD) FOR ALLO-329, A NEXT-GENERATION DUAL-TARGETED CD19/CD70 ALLOGENEIC CAR T, FOR THE TREATMENT OF LUPUS, MYOSITIS AND SCLERODERMA

07-04-2025
SOUTH SAN FRANCISCO, CALIF., APRIL 07, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATE

13-03-2025
SOUTH SAN FRANCISCO, CALIF., MARCH 13, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ...
Více zde

ALLOGENE THERAPEUTICS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

03-03-2025
SOUTH SAN FRANCISCO, CALIF., MARCH 03, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN MARCH INVESTOR CONFERENCE

26-02-2025
SOUTH SAN FRANCISCO, CALIF., FEB. 26, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS EXPANDS STRATEGIC PARTNERSHIP WITH FORESIGHT DIAGNOSTICS TO ADVANCE JOINT DEVELOPMENT ACTIVITIES OUTSIDE THE US ACROSS EUROPE, UK, CANADA, AND AUSTRALIA

25-02-2025
SOUTH SAN FRANCISCO, CALIF., FEB. 25, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY

13-02-2025
SOUTH SAN FRANCISCO, CALIF., FEB. 13, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS SECURES U.S. FDA IND CLEARANCE FOR ALLO-329, ADVANCING ITS NEXT-GENERATION ALLOGENEIC CAR T INTO AUTOIMMUNE DISEASES

28-01-2025
SOUTH SAN FRANCISCO, CALIF., JAN. 28, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

16-12-2024
SOUTH SAN FRANCISCO, CALIF., DEC. 16, 2024 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS ACKNOWLEDGES THE PASSING OF FOUNDING BOARD MEMBER DAVID BONDERMAN

12-12-2024
SOUTH SAN FRANCISCO, CALIF., DEC. 12, 2024 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN DECEMBER INVESTOR CONFERENCES

19-11-2024
SOUTH SAN FRANCISCO, CALIF., NOV. 19, 2024 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS PRESENTS PRECLINICAL DATA FOR ALLO-329, AN ALLOGENEIC CD19/CD70 DUAL CAR T FOR THE TREATMENT OF AUTOIMMUNE DISEASE AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE

18-11-2024
SOUTH SAN FRANCISCO, CALIF., NOV. 18, 2024 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ...
Více zde

ALLOGENE THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND BUSINESS UPDATE

07-11-2024
SOUTH SAN FRANCISCO, CALIF., NOV. 07, 2024 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ:...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-10-14 01:00:008-KStáhnout
2025-10-14 00:00:008-KStáhnout
2025-08-13 01:00:008-KStáhnout
2025-08-13 01:00:0010-QStáhnout
2025-08-13 00:00:008-KStáhnout
2025-08-13 00:00:0010-QStáhnout
2025-08-01 01:00:008-KStáhnout
2025-08-01 00:00:008-KStáhnout
2025-06-23 01:00:008-KStáhnout
2025-06-23 00:00:008-KStáhnout
2025-05-13 01:00:008-KStáhnout
2025-05-13 01:00:0010-QStáhnout
2025-05-13 00:00:008-KStáhnout
2025-05-13 00:00:0010-QStáhnout
2025-03-13 00:00:008-KStáhnout
2025-03-13 00:00:0010-KStáhnout
2025-03-12 23:00:008-KStáhnout
2025-03-12 23:00:0010-KStáhnout
2025-02-25 00:00:008-KStáhnout
2025-02-24 23:00:008-KStáhnout
2025-01-29 00:00:008-KStáhnout
2025-01-28 23:00:008-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-07 00:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:008-KStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-10-07 01:00:008-KStáhnout
2024-10-07 00:00:008-KStáhnout
2024-08-07 01:00:008-KStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:008-KStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-05-31 01:00:008-KStáhnout
2024-05-31 00:00:008-KStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-13 01:00:008-KStáhnout
2024-05-13 01:00:0010-QStáhnout
2024-05-13 00:00:008-KStáhnout
2024-05-13 00:00:0010-QStáhnout
2024-03-14 00:00:008-KStáhnout
2024-03-14 00:00:0010-KStáhnout
2024-03-13 23:00:008-KStáhnout
2024-03-13 23:00:0010-KStáhnout
2024-02-16 00:00:008-KStáhnout
2024-02-15 23:00:008-KStáhnout
2024-01-31 00:00:008-KStáhnout
2024-01-30 23:00:008-KStáhnout
2024-01-05 00:00:008-KStáhnout
2024-01-04 23:00:008-KStáhnout
2023-12-19 00:00:008-KStáhnout
2023-12-18 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-10-16 01:00:008-KStáhnout
2023-10-16 00:00:008-KStáhnout
2023-08-02 01:00:008-KStáhnout
2023-08-02 01:00:0010-QStáhnout
2023-08-02 00:00:008-KStáhnout
2023-08-02 00:00:0010-QStáhnout
2023-06-21 01:00:008-KStáhnout
2023-06-21 00:00:008-KStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-06-14 01:00:008-KStáhnout
2023-06-14 00:00:008-KStáhnout
2023-06-07 01:00:008-KStáhnout
2023-06-07 00:00:008-KStáhnout
2023-05-03 01:00:008-KStáhnout
2023-05-03 01:00:0010-QStáhnout
2023-05-03 00:00:008-KStáhnout
2023-05-03 00:00:0010-QStáhnout
2023-04-20 01:00:008-KStáhnout
2023-04-20 00:00:008-KStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2023-01-03 00:00:008-KStáhnout
2023-01-02 23:00:008-KStáhnout
2022-11-29 00:00:008-KStáhnout
2022-11-28 23:00:008-KStáhnout
2022-11-02 00:00:008-KStáhnout
2022-11-02 00:00:0010-QStáhnout
2022-11-01 23:00:008-KStáhnout
2022-11-01 23:00:0010-QStáhnout
2022-10-06 01:00:008-KStáhnout
2022-10-06 00:00:008-KStáhnout
2022-09-21 01:00:008-KStáhnout
2022-09-21 00:00:008-KStáhnout
2022-08-09 01:00:008-KStáhnout
2022-08-09 01:00:0010-QStáhnout
2022-08-09 00:00:008-KStáhnout
2022-08-09 00:00:0010-QStáhnout
2022-07-12 01:00:008-KStáhnout
2022-07-12 00:00:008-KStáhnout
2022-06-17 01:00:008-KStáhnout
2022-06-17 00:00:008-KStáhnout
2022-05-04 01:00:008-KStáhnout
2022-05-04 01:00:0010-QStáhnout
2022-05-04 00:00:008-KStáhnout
2022-05-04 00:00:0010-QStáhnout
2022-02-23 00:00:008-KStáhnout
2022-02-23 00:00:0010-KStáhnout
2022-02-22 23:00:008-KStáhnout
2022-02-22 23:00:0010-KStáhnout
2021-12-15 00:00:008-KStáhnout
2021-12-14 23:00:008-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-10-07 01:00:008-KStáhnout
2021-10-07 00:00:008-KStáhnout
2021-08-04 01:00:008-KStáhnout
2021-08-04 01:00:0010-QStáhnout
2021-08-04 00:00:008-KStáhnout
2021-08-04 00:00:0010-QStáhnout
2021-08-02 01:00:008-KStáhnout
2021-08-02 00:00:008-KStáhnout
2021-06-15 01:00:008-KStáhnout
2021-06-15 00:00:008-KStáhnout
2021-05-20 01:00:008-KStáhnout
2021-05-20 00:00:008-KStáhnout
2021-05-19 01:00:008-KStáhnout
2021-05-19 00:00:008-KStáhnout
2021-05-05 01:00:008-KStáhnout
2021-05-05 01:00:0010-QStáhnout
2021-05-05 00:00:008-KStáhnout
2021-05-05 00:00:0010-QStáhnout
2021-02-25 00:00:008-KStáhnout
2021-02-25 00:00:0010-KStáhnout
2021-02-24 23:00:008-KStáhnout
2021-02-24 23:00:0010-KStáhnout
2020-12-15 00:00:008-KStáhnout
2020-12-14 23:00:008-KStáhnout
2020-12-07 00:00:008-KStáhnout
2020-12-06 23:00:008-KStáhnout
2020-11-04 00:00:008-KStáhnout
2020-11-04 00:00:0010-QStáhnout
2020-11-03 23:00:008-KStáhnout
2020-11-03 23:00:0010-QStáhnout
2020-08-05 01:00:008-KStáhnout
2020-08-05 01:00:0010-QStáhnout
2020-08-05 00:00:008-KStáhnout
2020-08-05 00:00:0010-QStáhnout
2020-06-11 01:00:008-KStáhnout
2020-06-11 00:00:008-KStáhnout
2020-06-04 01:00:008-KStáhnout
2020-06-04 00:00:008-KStáhnout
2020-05-29 01:00:008-KStáhnout
2020-05-29 00:00:008-KStáhnout
2020-05-06 01:00:008-KStáhnout
2020-05-06 01:00:0010-QStáhnout
2020-05-06 00:00:008-KStáhnout
2020-05-06 00:00:0010-QStáhnout
2020-03-27 00:00:008-KStáhnout
2020-03-26 23:00:008-KStáhnout
2020-02-27 00:00:008-KStáhnout
2020-02-27 00:00:0010-KStáhnout
2020-02-26 23:00:008-KStáhnout
2020-02-26 23:00:0010-KStáhnout
2019-12-20 00:00:008-KStáhnout
2019-12-19 23:00:008-KStáhnout
2019-11-05 00:00:008-KStáhnout
2019-11-05 00:00:0010-QStáhnout
2019-11-04 23:00:008-KStáhnout
2019-11-04 23:00:0010-QStáhnout
2019-08-07 01:00:008-KStáhnout
2019-08-07 01:00:0010-QStáhnout
2019-08-07 00:00:008-KStáhnout
2019-08-07 00:00:0010-QStáhnout
2019-06-10 01:00:008-KStáhnout
2019-06-10 00:00:008-KStáhnout
2019-05-07 01:00:008-KStáhnout
2019-05-07 01:00:0010-QStáhnout
2019-05-07 00:00:008-KStáhnout
2019-05-07 00:00:0010-QStáhnout
2019-04-10 01:00:008-KStáhnout
2019-04-10 00:00:008-KStáhnout
2019-03-08 00:00:008-KStáhnout
2019-03-08 00:00:0010-KStáhnout
2019-03-07 23:00:008-KStáhnout
2019-03-07 23:00:0010-KStáhnout
2019-02-20 00:00:008-KStáhnout
2019-02-19 23:00:008-KStáhnout
2018-12-13 00:00:008-KStáhnout
2018-12-12 23:00:008-KStáhnout
2018-11-21 00:00:0010-QStáhnout
2018-11-20 23:00:0010-QStáhnout
2018-10-29 00:00:008-KStáhnout
2018-10-28 23:00:008-KStáhnout
2018-10-15 01:00:008-KStáhnout
2018-10-15 00:00:008-KStáhnout
preloader